10-QPeriod: Q2 FY2014

AbbVie Inc. Quarterly Report for Q2 Ended Jun 30, 2014

Filed August 7, 2014For Securities:ABBV

Summary

AbbVie Inc. reported its second-quarter and first-half 2014 financial results, showcasing moderate sales growth driven by its flagship product, HUMIRA. Total net sales increased by 5% year-over-year for both the three and six-month periods, reaching $4.9 billion and $9.5 billion, respectively. This growth was primarily attributed to strong performance in HUMIRA, which saw a significant 26% and 22% increase in sales for the respective periods, and contributions from other key products like Synthroid and Creon. Despite overall sales growth, AbbVie experienced a substantial decline in its lipid franchise due to loss of exclusivity, with sales down 82% and 77% in the respective periods. The company also noted a decrease in AndroGel sales due to market contraction. Net earnings showed a slight increase, with diluted EPS at $0.68 and $1.29 for the three and six months ended June 30, 2014, respectively. The company continued to invest heavily in Research and Development, with R&D expenses increasing by 18% and 20% in the respective periods, reflecting its commitment to pipeline advancement. Notably, AbbVie announced a significant subsequent event: a recommended combination with Shire plc, which is expected to create a larger and more diversified biopharmaceutical company.

Financial Highlights

51 data points
Beta

Revenue

$4.93B

77.4% Gross Margin

Net Income

$1.10B

22.3% Net Margin

EPS (Diluted)

$0.68

Total Assets

$29.05B

Cash & Equivalents

$9.09B

Free Cash Flow

$1.57B

Financial Statements
Beta
Revenue$4.93B
Cost of Revenue$1.11B
Gross Profit$3.81B
SG&A Expenses$1.45B
Operating Expenses$3.41B
Operating Income$1.51B
Interest Expense$73.00M
Net Income$1.10B
EPS (Basic)$0.69
EPS (Diluted)$0.68
Shares Outstanding (Basic)1.59B
Shares Outstanding (Diluted)1.61B

Key Highlights

  • 1AbbVie reported a 5% increase in net sales for both the three and six months ended June 30, 2014, reaching $4.9 billion and $9.5 billion respectively.
  • 2HUMIRA sales demonstrated robust growth, increasing by 26% and 22% for the three and six-month periods, respectively, driven by strong market performance and new indications.
  • 3Lipid franchise sales experienced a significant decline of 82% and 77% due to loss of exclusivity and generic competition.
  • 4Research and Development expenses increased by 18% and 20% year-over-year, indicating continued investment in pipeline development.
  • 5Diluted Earnings Per Share (EPS) were $0.68 for the three months and $1.29 for the six months ended June 30, 2014.
  • 6The company announced a subsequent event involving a recommended combination with Shire plc, aimed at creating a larger, diversified biopharmaceutical entity.
  • 7AbbVie generated $2.3 billion in cash flow from operating activities for the first six months of 2014.

Frequently Asked Questions

AbbVie's net sales growth was primarily driven by the strong performance of its flagship product, HUMIRA, which saw a significant increase in sales. Growth from other key products like Synthroid and Creon also contributed, though this was partially offset by the ongoing impact of lost exclusivity in the lipid franchise.

AbbVie is experiencing a substantial decline in sales from its lipid franchise due to generic competition. The company is focusing on maximizing the value of its existing portfolio through new indications and geographic expansion, while also advancing its pipeline of new medicines to compensate for revenue losses from products facing generic challenges.

The announced recommended combination with Shire plc is a major strategic development. It is intended to create a larger and more diversified biopharmaceutical company with enhanced financial capacity for future investments and shareholder returns. The transaction is subject to regulatory and shareholder approvals.

AbbVie has increased its investment in R&D, with expenses rising by 18% and 20% for the three and six months ended June 30, 2014, respectively. This reflects the company's commitment to advancing its pipeline, particularly its mid- and late-stage assets across key therapeutic areas like immunology, oncology, and virology.